BioCentury
ARTICLE | Financial News

Antengene raises $21M series A

August 16, 2017 10:34 PM UTC

Antengene Corp. (Shanghai, China) raised $21 million in a series A round led by Qiming Venture Partners with participation by TF Capital, HG Capital and Tigermed Investment.

Antengene has exclusive rights to ATG-008 (CC-223), an inhibitor of mammalian target of rapamycin complex 1 (mTORC1) and mTORC2, from Celgene Corp. (NASDAQ:CELG) in China, South Korea and certain other East and Southeast Asian territories, excluding Japan...